Spinal motor neurons are large projection neurons that form the final common pathway for voluntary movement. Located in the ventral horn of the spinal cord, these neurons innervate skeletal muscle fibers and are critical for motor control. They are selectively vulnerable in several neurodegenerative disorders, particularly amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).
¶ Cell Markers and Molecular Signature
- Choline acetyltransferase (ChAT) — enzyme synthesizing acetylcholine
- VaChT (SLC18A3) — vesicular acetylcholine transporter
- Motor neuron-specific transcription factors: Hb9, Islet1, Lhx3
- SMN complex proteins — critical for spliceosome function (deficient in SMA)
- TDP-43 (TARDBP) — RNA-binding protein aggregating in >95% of ALS cases
- FUS — RNA-binding protein aggregating in some ALS cases
- C9orf72 — hexanucleotide repeat expansion in familial ALS/FTD
Large alpha motor neurons (30-70 μm cell body) with extensive dendritic arborization receiving synaptic input from:
- Upper motor neurons (corticospinal tract)
- Sensory neurons (Ia, II afferents)
- Interneurons (Renshaw cells, Ia inhibitory)
Axons exit via ventral roots to innervate extrafusal muscle fibers. Each motor neuron controls 100-1000 muscle fibers forming a motor unit.
- TDP-43 pathology — cytoplasmic inclusions in >95% of ALS cases
- Excitotoxicity — glutamate-induced calcium overload via AMPA/kainate receptors
- Mitochondrial dysfunction — energy deficit and ROS generation
- Axonal transport defects — impaired movement of organelles and proteins
- Neuroinflammation — microglial and astrocytic activation releasing toxic factors
- Non-neuronal cells — astrocytes and microglia become toxic to motor neurons
- SMN protein deficiency — due to SMN1 deletion/mutation
- Spliceosome dysfunction — defective splicing of critical neuronal transcripts
- Neuromuscular junction denervation — earliest pathological change
- Selective vulnerability — why lower motor neurons are specifically affected remains unclear
Various subtypes affect motor neurons, with demyelinating (CMT1) and axonal (CMT2) forms causing motor weakness and atrophy.
- Riluzole — glutamate antagonist modestly extends survival
- Edaravone — free radical scavenger approved for ALS
- ASO therapy — antisense oligonucleotides targeting SOD1, C9orf72
- Gene therapy — AAV-vector delivered SMN1 for SMA (Zolgensma)
- Cell replacement — neural progenitor transplantation in early trials
- Taylor et al., ALS: Molecular Pathophysiology (2016)
- Bowerman et al., Therapeutic Strategies in ALS (2017)
- Fischer et al., TDP-43 in ALS (2019)
- Monani, Spinal Muscular Atrophy (2005)